Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.

Cancers (Basel) · 2012 · PMC3712722 · PMID 24213509

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

showed a trendp = 0.055so close (0.05 < p ≤ 0.1)

Patients who had greater PSA-specific T cell responses by ELISPOT also showed a trend toward longer survival ( p = 0.055), and 12/15 patients evaluated lived longer than predicted by the Halabi nomogram ( p = 0.035) [ 82 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.